Janssen, “We’ll carry out extensive & global Phase II clinical trial of Hanmi Pharm’s obesity and diabetes biologic”

Hanmi Pharm’s new obesity & diabetes biologic being developed by Janssen  HM12525A(Janssen Code Name: JNJ-64565111) will additionally take an extensive global Phase II clinical trial.

This Phase II clinical trial will evaluate safety and efficacy on 188 extreme obesity patients with diabetes. Janssen officially registered this at the U.S. clinical study registry website ClinicalTrials.gov on t...